Peloton Therapeutics: REFILE-UPDATE 2-Merck buys Peloton to expand its kidney cancer treatment portfolio

U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate.